Condition: Rheumatoid Arthritis (RA) · Sponsor: SynAct Pharma Aps
The study is a randomized, double blind, placebo-controlled, dose response, phase II, multicentre trial to evaluate the efficacy and safety of oral AP1189 administered at the doses of 40, 70, or 100 mg for 12 weeks in combination with methotrexate, in DMARD-naïve participants with early rheumatoid arthritis and active inflammation.
This description comes directly from the study's public registry record.
Thomas Jonassen, MD · +45 4015 6669 · tj@synactpharma.com
Always discuss trial participation with your own doctor first.
| Nouvelle Clinical Research LLC | Cutler Bay, Florida, United States | Recruiting |
| Millennium Medical Research LLC | Miami, Florida, United States | Recruiting |
| Altoona Center for Clinical Research | Duncansville, Pennsylvania, United States | Recruiting |
| Diagnostic Consultative Center Aleksandrovska | Sofia, Bulgaria | Recruiting |
| Medical Center Tera Medico | Vratsa, Bulgaria | Recruiting |
| Sanos Clinic Herlev | Herlev, Denmark | Recruiting |
| IMSP Spitalul Clinic Municipal "Sfanta Treime" | Chisinau, Moldova | Recruiting |
| M2Mmed | Chorzów, Poland | Recruiting |
| Vita Longa Sp. z o. o. | Katowice, Poland | Recruiting |
| Medyczne Centrum Hetmańska | Poznan, Poland | Recruiting |
| DC-MED Michal Kowalski S.K. | Swidnica, Poland | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06671054